Werewolf Therapeutics, Inc. (HOWL) Misses Q2 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. LDOS
8. HUM
9. CSCO
10. KTOS

Go back to Werewolf Therapeutics, Inc. (HOWL) Misses Q2 EPS by 23c

Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

August 11, 2022 7:00 AM EDT

- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors -

- Submission of IND application for WTX-330 planned in 2H22 -

- Q2 cash and cash equivalents balance of $145.7 million provides runway through at least the fourth quarter of 2023 -

WATERTOWN, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the Company or Werewolf) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the... More